Martha Morrell - 12 Feb 2024 Form 4 Insider Report for NeuroPace Inc (NPCE)

Role: CHIEF MEDICAL OFFICER
Signature: /s/ Leah Akin, Attorney-in-Fact
Issuer symbol: NPCE
Transactions as of: 12 Feb 2024
Net transactions value: +$1,300
Form type: 4
Filing time: 25 Feb 2025, 18:51:01 UTC
Previous filing: 06 Feb 2024
Next filing: 28 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NPCE	Common Stock	Options Exercise	$1,300	+50,000	+45%	$0.0260	160,327	12 Feb 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NPCE	Stock Option (Rt to Buy)	Options Exercise	$0	-50,000	-26%	$0.000000	140,449	12 Feb 2024	Common Stock	50,000	$0.0260	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 13,847 shares acquired pursuant to the NeuroPace, Inc. 2021 Employee Stock Purchase Plan between April 22, 2021 and June 7, 2024.
F2	1/48th of the shares subject to the option vest in equal monthly installments commencing September 19, 2020. If, at the time of the initial public offering, less than 232,371 of the shares subject to this option remain unvested, an amount of shares subject to this option shall vest and become immediately exercisable immediately prior to the offering such that a total of 232,371 shares subject to this option will be vested and immediately exercisable, subject to Dr. Morrells continued service with NeuroPace, Inc. Following such acceleration, the remaining unvested shares subject to this option will continue to vest in equal monthly installments over 48 months.

Content

Includes 13,847 shares acquired pursuant to the NeuroPace, Inc. 2021 Employee Stock Purchase Plan between April 22, 2021 and June 7, 2024.

1/48th of the shares subject to the option vest in equal monthly installments commencing September 19, 2020. If, at the time of the initial public offering, less than 232,371 of the shares subject to this option remain unvested, an amount of shares subject to this option shall vest and become immediately exercisable immediately prior to the offering such that a total of 232,371 shares subject to this option will be vested and immediately exercisable, subject to Dr. Morrells continued service with NeuroPace, Inc. Following such acceleration, the remaining unvested shares subject to this option will continue to vest in equal monthly installments over 48 months.